EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

P16/Ki67 dual staining versus cytology for identifying high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) in triage management of HR-HPV-positive women: a systematic review and meta-analysis

Hang Zhou iD, Yu Dai iD, Hua Zhang iD, Yuan Yang iD, Ruoji Pi iD, Lingling Zhu iD, Wen Chen iD

Journal of Gynecologic Oncology · 2026

DOI: 10.3802/jgo.2026.37.e68 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Hang Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sc…. Hauptthemen laut MEDLINE: Ki-67 Antigen, Uterine Cervical Dysplasia, Cyclin-Dependent Kinase Inhibitor p16, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Roche Diagnostics (Shanghai) Limited, Beijing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The co-expression of P16 and Ki67 suggests the presence of high-grade cervical intraepithelial neoplasia, which makes P16/Ki67 dual staining a promising marker in cervical cancer screening. This study provides a systemic review of the established evidence on the performance of P16/Ki67 versus cytology in detecting cervical intraepithelial neoplasia (CIN)2+/CIN3+ among high-risk human papillomavirus (HR-HPV)-positive women and HR-HPV-positive individuals with cytology-negative results for triage management. METHODS: Studies published from database inception to April 26, 2024, were systematically searched. A total of 26 studies were eventually included in the study, comprising 26,424 women, with 14,625 classified as P16/Ki67-positive and 11,799 as P16/Ki67-negative. RESULTS: In the triage management of HR-HPV-positive women, P16/Ki67 achieved sensitivities of 85% for CIN2+ and 88% for CIN3+, with specificities of 63% and 57%, respectively. In comparison, cytology showed lower sensitivities of 76% for CIN2+ and 79% for CIN3+, with lower specificities of 57% and 54%. In triage management of human papillomavirus (HPV)-positive but cytology-negative women, 18.48% of the HPV-positive patients, initially missed by cytology, were correctly retrieved by the addition of P16/Ki67. A negative P16/Ki67 test result reduced the risk of underlying CIN3+ to 4% for HR-HPV-positive individuals and 1% for the HR-HPV-positive individuals with cytology-negative results, prompting a recommendation for follow-up at 1-year intervals. CONCLUSION: P16/Ki67 exhibits diagnostic superiority over liquid-based cytology in detecting CIN2+/CIN3+, among HR-HPV-positive women. Furthermore, its ability to identify patients missed by cytology highlights its value as a complementary tool for triage of HR-HPV-positive but cytology-negative population. By effectively reducing unnecessary colposcopy referrals, P16/Ki67 conserves healthcare resources and improves outcomes. TRIAL REGISTRATION: PROSPERO Identifier: CRD42024567623.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ki-67 AntigenUterine Cervical DysplasiaCyclin-Dependent Kinase Inhibitor p16Uterine Cervical NeoplasmsPapillomavirus InfectionsHumansFemaleTriageSensitivity and SpecificityBiomarkers, TumorHuman Papillomavirus VirusesPapillomaviridae

Stichwörter der Autor:innen

Cervical CancerHuman PapillomavirusKi-67 AntigenMeta-AnalysisTriagep16(INK4A)

Substanzen

Ki-67 AntigenCyclin-Dependent Kinase Inhibitor p16Biomarkers, TumorCDKN2A protein, humanMKI67 protein, human

Autor:innen und Institutionen

  • Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.
  • Mianyang Maternal and Child Health Care Hospital, Mianyang, China.
  • Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. chenwen@cicam…

ORCID-Profile: Hang Zhou, Yu Dai, Hua Zhang, Yuan Yang, Ruoji Pi, Lingling Zhu, Wen Chen

Förderung

  • Roche Diagnostics (Shanghai) Limited
  • Beijing Natural Science Foundation

Zitieren

APA

Zhou, H., Dai, Y., Zhang, H., Yang, Y., Pi, R., Zhu, L., & Chen, W. (2026). P16/Ki67 dual staining versus cytology for identifying high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) in triage management of HR-HPV-positive women: a systematic review and meta-analysis. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2026.37.e68

Vancouver

Zhou H, Dai Y, Zhang H, Yang Y, Pi R, Zhu L, et al. P16/Ki67 dual staining versus cytology for identifying high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) in triage management of HR-HPV-positive women: a systematic review and meta-analysis. Journal of Gynecologic Oncology. 2026. doi:10.3802/jgo.2026.37.e68

BibTeX
@article{Zhou2026,
  author = {Zhou, Hang and Dai, Yu and Zhang, Hua and Yang, Yuan and Pi, Ruoji and Zhu, Lingling and Chen, Wen},
  title = {P16/Ki67 dual staining versus cytology for identifying high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) in triage management of HR-HPV-positive women: a systematic review and meta-analysis},
  journal = {Journal of Gynecologic Oncology},
  year = {2026},
  doi = {10.3802/jgo.2026.37.e68}
}
Kostenlos starten →